Board Update
Summary by AI BETAClose X
13 November 2026
Molecule Group plc
(the "Company", "Group" or "Molecule")
Board Update
Molecule Group plc, the Company building a leading regulated UK ePharmacy through buy-and-build, is pleased to announce the appointment of Andrew Houghton as an independent Non-Executive Director with immediate effect.
Mr Houghton brings considerable commercial, consumer-brand and digital experience, having previously held senior roles at Nike Inc from July 2012 to May 2024 and at Unilever PLC, where he established a new business unit to develop the Unilever UK eCommerce strategy. Prior to this, Mr Houghton spent 8 years at Accenture in the management consulting practice. Mr Houghton currently serves as Managing Director of Lands’ End Europe Limited, the European subsidiary of Lands’ End Corporation, a leading online clothing retailer.
The Company also announces that Dr David Wong, Non-Executive Director, steps down from the board of directors (the “Board”) with immediate effect. The Board would like to thank David for his contribution to the Company and wishes him well for the future.
Susan Clement Davies, Chair of Molecule, commented: “We are delighted to welcome Andrew to Molecule. His considerable commercial, consumer-brand and digital experience will be invaluable as we grow the business and progress our buy-and-build strategy.”
Andrew John Houghton, aged 50, is currently a director of Lands’ End Europe Limited. Andrew has held no other directorships/partnerships in the past five years.
Save as set out above, there is no further information to be disclosed in relation to Andrew Houghton’s appointment to the Board pursuant to AIM Rule 17 or paragraph (g) of Schedule Two of the AIM Rules for Companies.
- Ends -
For further information please contact:
|
Molecule Group plc Michael Kraftman, Chief Executive Officer Keith Butcher, Chief Financial Officer Brendan O’Brien, Chief Operating Officer |
|
|
Canaccord Genuity Limited
Simon Bridges / Harry Pardoe / Elizabeth Halley-Stott |
Tel: +44 (0) 20 7523 8000 |
|
Alma Strategic Communications Justine James / Josh Royston / Sam Modlin / Will Merison |
Tel: +44 (0)20 3405 0205 |
Notes to Editors
Molecule Group plc (AIM: MOL) is building a leading regulated ePharmacy platform, through its disciplined buy-and-build strategy. Following the acquisitions of CloudRx, Webmed and Hyperdrug in March 2026, the Group has established a diversified, profitable platform spanning B2B prescription fulfilment and B2C digital pharmacy services, with a high proportion of recurring revenues and strong cash generation. Future growth is expected to be supported through the acquisition of complementary businesses, expansion into new sectors or markets, and investment in long-term assets.
The Group is led by an experienced management team with deep healthcare, eCommerce and buy-and-build expertise. For more information, visit investors.molecule.co.uk.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund